Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Crenolanib is a second-generation, type I tyrosine kinase in...
| Class:Id | Summation:9703048 |
|---|---|
| _displayName | Crenolanib is a second-generation, type I tyrosine kinase in... |
| _timestamp | 2020-11-06 19:54:17 |
| created | [InstanceEdit:9703049] Rothfels, Karen, 2020-10-05 |
| modified | [InstanceEdit:9704328] Rothfels, Karen, 2020-10-07 [InstanceEdit:9706547] Rothfels, Karen, 2020-11-06 |
| text | Crenolanib is a second-generation, type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Lim et al, 2017). It is currently in phase III clinical trials for treatment of FLT3-positive AML. The following FLT3 mutants are resistant to crenolanib-mediated inhibition: FLT3 F691L (Galanis et al, 2014) FLT3 D835H (Galanis et al, 2014) |
| (summation) | [FailedReaction:9702583] crenolanib-resistant FLT3 mutants don't bind crenolanib [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Crenolanib is a second-generation, type I tyrosine kinase in... (9703048)
